Kinase Assay Offers New Approach to Analyzing Oncology Targets

The assay will enable scientists to study all kinases and adenine triphosphatases (ATPases), providing a new approach to analyzing oncology targets.

The HTRF Transcreener ADP assay is a homogeneous, non-radioactive solution for kinases and ATPases. The assay measures the generation of ADP, which is directly detected by a specific antibody labeled with europium (Eu) 3+ cryptate and correlates tightly with the amount of phosphorylated substrate.

The assay is compatible with any substrate because it measures the ADP and not the substrate itself. The enzyme-free detection mode also provides an alternative with less interference and a lower false-positive rate than assays that measure ATP depletion. This is important when measuring difficult kinases, such as ones where no specific antibody is available.

The assay combines two technologies: Cisbio's (Bagnols-sur-Cèze, France) HTRF, a highly sensitive, robust technology for the detection of molecular interactions in vitro, which is widely used for primary and secondary screening phases of drug development; and Transcreener, a proprietary ADP immunodetection technology platform for kinases and other ATP-utilizing enzymes, developed by BellBrook Labs (Madison, WI, USA), a provider of HTS tools.

"Transcreener, like HTRF, is a reliable and robust technology, which is why our partnership with BellBrook makes sense,” said François Degorce, head of HTRF marketing and business development at Cisbio. "We are always looking to complement our kinase offering and reinforce our expertise in this field, and the combination of two such powerful technologies means that HTRF Transcreener ADP will do just that.”

HTRF Transcreener ADP does not require additional training or technology for existing HTRF customers to use it. Therefore adoption of the assay is straightforward, and scientists can now use a single technology for all kinase assays, and save valuable development time and costs. The HTRF Transcreener ADP assay is sold through Cisbio's own sales networks in the United States and Europe, and through its exclusive distributors in India and Japan.

Cisbio is a global developer of products and technologies used in nuclear medicine, in vitro diagnostics, and assay development for drug screening procedures. The company pioneered the field of homogenous fluorescence methodologies via its proprietary technology, HTRF, a highly sensitive, robust technology for the detection of molecular interactions.


Related Links:
Cisbio
BellBrook Labs